Skip To Main Content
C. Yoo on Muck Rack

C. Yoo

As seen in: Color Research & Application, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to C. Yoo’s profile

Articles by C. Yoo

Changing nurse licensing examinations: media analysis and implications of the Canadian experience

|
By L. McGillis Hall, M. Lalonde, J. Kashin, C. Yoo
| Color Research & Application Verified
This study examines perceptions of the implementation of National Council Licensing Examination in Canada through a content analysis of articles in the media. Public opinions of nursing in the media have been acknowledged as important for the profession, specifically in relation to their portrayal of nursing.
Open in Who Shared Issue with article?

261P Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplatin-containing regimen

|
By C. Yoo, B. S. Kim, K-P. Kim, J. Cheon
| Annals of Oncology Verified
261P Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplatin-containing regimen J. Cheon, C. Yoo, B. Kim, K-P. Kim, J-L. Lee, T.W. Kim, B-Y. Ryoo and H-M. Chang Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea Background: Pancreatic acinar cell carcinoma (ACC) is a rare cancer of the exocrine pancreas.
Open in Who Shared Issue with article?

Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma

|
By J. H. Kang, K-P. Kim, C. Yoo, J-L. Lee
| Annals of Oncology Verified
Background: Neoadjuvant treatment strategy has been investigated for patients (pts) with borderline resectable pancreatic cancer (BRPC). Although FOLFIRINOX has been more widely used based on its success in patients with metastatic disease, there is lack of data based on the prospective randomized trial in this setting. Therefore, we performed retrospective analysis comparing the efficacy of FOLFIRINOX and gemcitabine-based regimen. Methods: Between February 2013 and December 2014, a total of 18 …
Open in Who Shared Issue with article?

Efficacy and safety of targeted agents for treatment of gastroenteropancreatic (GEP) neuroendocrine tumor (NET)

|
By K-P. Kim, H. Chae, C. Yoo, H-M. Chang
| Annals of Oncology Verified
Background: Efficacy and safety of targeted agents, such as everolimus and sunitinib, have been demonstrated in the prospective trials for patients with GEP-NET. Considering heterogeneous clinical features of NET, evaluation of real-world outcomes with these agents are necessary. We retrospectively analyze the treatment outcomes of everolimus and sunitinib for patients (pts) with GEP-NET.
Open in Who Shared Issue with article?

High-Level Ciprofloxacin-Resistant Campylobacter jejuni Isolates Circulating in Humans and Animals in Incheon, Republic of Korea

|
By J. Y. Kim, S. J. Kim, S. Jeon, S. J. Hong, C. Yoo, M. Y. Lee, I. Cha, G. T. Chung, M. -J. Huh, Y. -H. Kang
| Color Research & Application Verified
Campylobacter jejuni is one of the major causative pathogens of outbreaks or sporadic cases of diarrhoeal diseases worldwide. In this study, we compared the phenotypic and genetic characteristics of C. jejuni isolates of human and food-producing animal origins in Korea and examined the genetic relatedness between these two groups of isolates. Regardless of isolation source, all C.
Open in Who Shared Issue with article?
Show More